SI2361924T1 - Postopek za pripravo zmesi trifluoroacetil glatiramer acetata ob uporabi očiščene bromovodikove kisline - Google Patents

Postopek za pripravo zmesi trifluoroacetil glatiramer acetata ob uporabi očiščene bromovodikove kisline

Info

Publication number
SI2361924T1
SI2361924T1 SI200531830T SI200531830T SI2361924T1 SI 2361924 T1 SI2361924 T1 SI 2361924T1 SI 200531830 T SI200531830 T SI 200531830T SI 200531830 T SI200531830 T SI 200531830T SI 2361924 T1 SI2361924 T1 SI 2361924T1
Authority
SI
Slovenia
Prior art keywords
mixtures
preparation
hydrobromic acid
glatiramer acetate
trifluoroacetyl glatiramer
Prior art date
Application number
SI200531830T
Other languages
English (en)
Inventor
Ben-Zion Dolitzky
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36037047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2361924(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of SI2361924T1 publication Critical patent/SI2361924T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SI200531830T 2004-09-09 2005-09-09 Postopek za pripravo zmesi trifluoroacetil glatiramer acetata ob uporabi očiščene bromovodikove kisline SI2361924T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60884304P 2004-09-09 2004-09-09
EP10194363.7A EP2361924B1 (en) 2004-09-09 2005-09-09 Process for the preparation of mixtures of trifluoroacetyl glatiramer acetate using purified hydrobromic acid

Publications (1)

Publication Number Publication Date
SI2361924T1 true SI2361924T1 (sl) 2014-04-30

Family

ID=36037047

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200530934T SI1799703T1 (sl) 2004-09-09 2005-09-09 Postopek za pripravo zmesi polipeptidov z uporabo oŽŤišŽŤene bromovodikove kisline
SI200531482T SI2177528T1 (sl) 2004-09-09 2005-09-09 Postopek za pripravo zmesi trifluoroacetil glatiramer acetata z uporabo očiščene bromovodikove kisline
SI200531830T SI2361924T1 (sl) 2004-09-09 2005-09-09 Postopek za pripravo zmesi trifluoroacetil glatiramer acetata ob uporabi očiščene bromovodikove kisline

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI200530934T SI1799703T1 (sl) 2004-09-09 2005-09-09 Postopek za pripravo zmesi polipeptidov z uporabo oŽŤišŽŤene bromovodikove kisline
SI200531482T SI2177528T1 (sl) 2004-09-09 2005-09-09 Postopek za pripravo zmesi trifluoroacetil glatiramer acetata z uporabo očiščene bromovodikove kisline

Country Status (28)

Country Link
US (2) US7495072B2 (sl)
EP (3) EP2177528B1 (sl)
JP (1) JP5149008B2 (sl)
KR (1) KR101317131B1 (sl)
CN (1) CN101166754B (sl)
AT (2) ATE454396T1 (sl)
AU (1) AU2005282249B2 (sl)
BR (1) BRPI0515033B1 (sl)
CA (1) CA2579656C (sl)
CY (1) CY1110280T1 (sl)
DE (1) DE602005018800D1 (sl)
DK (3) DK2361924T3 (sl)
ES (3) ES2382298T3 (sl)
HK (3) HK1100780A1 (sl)
HR (3) HRP20100164T1 (sl)
IL (2) IL181596A (sl)
IS (1) IS8622A (sl)
MX (1) MX2007002760A (sl)
NO (1) NO20071632L (sl)
NZ (1) NZ554018A (sl)
PL (3) PL1799703T3 (sl)
PT (3) PT1799703E (sl)
RS (3) RS51257B (sl)
RU (1) RU2388764C2 (sl)
SI (3) SI1799703T1 (sl)
UA (1) UA91029C2 (sl)
WO (1) WO2006029393A2 (sl)
ZA (1) ZA200702591B (sl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
ES2349033T3 (es) * 2001-12-04 2010-12-22 Teva Pharmaceutical Industries, Ltd. Procedimientos para la medida de la actividad del acetato de glatiramer.
US20070244056A1 (en) * 2004-03-03 2007-10-18 Liat Hayardeny Combination Therapy With Glatiramer Acetate and Riluzole
SI1797109T1 (sl) * 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe
CN101166754B (zh) * 2004-09-09 2014-04-23 特瓦制药工业有限公司 使用纯化的氢溴酸制备多肽混合物的方法
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
CA2583589C (en) * 2004-10-29 2012-04-24 Sandoz Ag Processes for preparing glatiramer
MX2007009296A (es) * 2005-02-02 2007-09-21 Teva Pharma Proceso para producir mezclas de polipeptidos usando hidrogenolisis.
EP1848415B1 (en) * 2005-02-17 2013-04-03 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
EP1891233A4 (en) * 2005-04-25 2010-03-24 Yeda Res & Dev MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
US20090035816A1 (en) * 2007-08-02 2009-02-05 Scinopharm Taiwan Ltd. Process for the preparation of a polypeptide
AU2008330093A1 (en) * 2007-11-28 2009-06-04 Yeda Research And Development Co., Ltd. Method of delaying the onset of clinically definite multiple sclerosis
RU2010146489A (ru) 2008-04-16 2012-05-27 Момента Фармасьютикалз, Инк. (Us) Анализ композиций сополимера аминокислот
PL2307448T3 (pl) * 2008-08-07 2015-10-30 Sigma Aldrich Co Llc Wytwarzanie polilizyny i poliornityny o małym ciężarze cząsteczkowym z wysoką wydajnością
NZ590872A (en) * 2008-08-07 2012-10-26 Scinopharm Taiwan Ltd Process for the preparation of polypeptide glatiramer acetate
ES2523732T5 (es) * 2009-04-03 2023-10-23 Momenta Pharmaceuticals Inc Control de composiciones de copolímeros
LT3199172T (lt) 2009-08-20 2018-10-25 Yeda Research And Development Co., Ltd. Dozavimo režimas, skirtas išsėtinei sklerozei
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
MX2012012489A (es) * 2010-04-27 2012-12-17 Reddys Lab Ltd Dr Preparacion de polipeptidos y sales de los mismos.
PT2627669T (pt) 2010-10-11 2016-11-24 Teva Pharma Biomarcadores de citocina como biomarcadores preditivos de resposta clínica para acetato de glatirâmero
WO2012123959A2 (en) 2011-02-14 2012-09-20 Usv Limited Copolymer-1, process for preparation and analytical methods thereof
JP5701103B2 (ja) * 2011-03-02 2015-04-15 昭和シェル石油株式会社 潤滑油のための消泡剤組成物及びそれを用いた消泡方法
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
WO2013009864A1 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Structure assessment of heterogeneous polypeptide mixtures
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
WO2013055683A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
CN102717992A (zh) * 2012-05-30 2012-10-10 苏州市旭洋工业搪瓷厂 一种搪玻璃溴素贮罐
CN102718963B (zh) * 2012-06-19 2014-10-15 深圳翰宇药业股份有限公司 聚合物多肽的制备方法
US9617596B2 (en) 2012-10-10 2017-04-11 Teva Pharmaceutical Industries, Ltd. Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
EP3062792A1 (en) 2013-11-01 2016-09-07 Celgene International II Sarl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
CN104844697B (zh) 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 醋酸格拉替雷的制备方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
WO2018178973A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
US20190202984A1 (en) * 2018-01-03 2019-07-04 Kinbio Ltd. Process of preparing glatiramer acetate

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846550A (en) 1971-01-21 1974-11-05 H Akrongold Cosmetic skin powder containing urea
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
JPS54119499A (en) * 1978-03-09 1979-09-17 Shionogi & Co Ltd Triazolobenzodiazepin derivative
JPS6053535A (ja) 1983-09-02 1985-03-27 Nitto Boseki Co Ltd 規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
BR8606731A (pt) 1985-06-18 1987-08-11 Univ Emory Copolimeros biologicamente ativos e metodos de estimulacao do sistema imune de animais e humanos
DD257174A3 (de) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
SU1469826A1 (ru) 1986-05-30 1995-11-20 Институт Высокомолекулярных Соединений Ан Ссср Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения
SU1690368A1 (ru) 1989-07-20 1995-08-20 Институт Высокомолекулярных Соединений Ан Ссср Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения
DE3930733A1 (de) 1989-09-14 1991-03-28 Roehm Gmbh Verfahren zur herstellung eines komplexierten arzneimittels
USH1312H (en) * 1992-05-28 1994-05-03 Cytogen Corporation Method for the preparation of gyk-dtpa
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
FR2750423B1 (fr) 1996-06-28 1998-08-14 Rhone Poulenc Chimie Procede d'hydrogenation asymetrique d'un compose cetonique
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
KR20010015639A (ko) 1997-09-30 2001-02-26 스즈키 다다시 술포닐 유도체
US5872122A (en) * 1997-10-16 1999-02-16 Monsanto Company Pyrimidinylamidino β-amino acid derivatives useful as inhibitors of platelet aggregation
US5965047A (en) 1997-10-24 1999-10-12 Steag Ast Rapid thermal processing (RTP) system with rotating substrate
GB9724627D0 (en) 1997-11-20 1998-01-21 Genencor Int Bv Gram positive microorganism formate pathway
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
AU775073C (en) 1998-11-12 2007-05-03 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
US6114649A (en) 1999-07-13 2000-09-05 Duran Technologies Inc. Anode electrode for plasmatron structure
WO2001018248A2 (en) 1999-09-03 2001-03-15 The University Of Iowa Research Foundation Quorum sensing signaling in bacteria
DE19944003C1 (de) 1999-09-14 2001-03-22 Baumeister & Ostler Gmbh Co Faltbare Trenneinrichtung
US6844314B2 (en) * 2000-01-20 2005-01-18 Yeda Research Development Co., Ltd. Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
IL150895A0 (en) 2000-02-18 2003-02-12 Teva Pharma Oral, nasal and pulmonary formulations of copolymer-1
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
NZ520282A (en) 2000-06-07 2004-09-24 Yeda Res & Dev The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
JP3698984B2 (ja) 2000-11-10 2005-09-21 ヤマウチ株式会社 シュープレス用ベルト
US6624180B2 (en) * 2000-11-20 2003-09-23 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
JP3661935B2 (ja) 2001-06-20 2005-06-22 ソニー株式会社 情報処理装置および方法、記録媒体、並びにプログラム
ES2349033T3 (es) * 2001-12-04 2010-12-22 Teva Pharmaceutical Industries, Ltd. Procedimientos para la medida de la actividad del acetato de glatiramer.
US7527981B2 (en) 2002-05-09 2009-05-05 Dennis Farwell Bioweapon-detecting fibrous-network products and methods for making same
AU2003283152A1 (en) * 2002-11-13 2004-06-03 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
CA2411786C (en) 2002-11-13 2009-01-27 Brantford Chemicals Inc. A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
DE10353960B4 (de) 2003-10-16 2006-03-23 Vertilas Gmbh Oberflächenemittierender Halbleiterlaser mit strukturiertem Wellenleiter
CN101166754B (zh) * 2004-09-09 2014-04-23 特瓦制药工业有限公司 使用纯化的氢溴酸制备多肽混合物的方法
SI1797109T1 (sl) 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe
MX2007009296A (es) 2005-02-02 2007-09-21 Teva Pharma Proceso para producir mezclas de polipeptidos usando hidrogenolisis.
EP1891233A4 (en) * 2005-04-25 2010-03-24 Yeda Res & Dev MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
WO2007072865A1 (ja) 2005-12-22 2007-06-28 Pioneer Corporation 施設情報配信装置、通信端末、施設情報配信方法、情報出力方法、プログラム、および記録媒体

Also Published As

Publication number Publication date
HRP20140216T1 (hr) 2014-06-06
EP2177528B1 (en) 2011-12-07
ES2382298T3 (es) 2012-06-07
NZ554018A (en) 2009-06-26
PL2361924T3 (pl) 2014-08-29
RS51257B (sr) 2010-12-31
DK2361924T3 (en) 2014-03-10
HK1100780A1 (en) 2007-09-28
ES2338138T3 (es) 2010-05-04
KR101317131B1 (ko) 2013-10-10
EP2177528A1 (en) 2010-04-21
AU2005282249A1 (en) 2006-03-16
EP2361924A1 (en) 2011-08-31
US20070021324A1 (en) 2007-01-25
DK1799703T3 (da) 2010-04-19
UA91029C2 (uk) 2010-06-25
IS8622A (is) 2007-03-16
HRP20120209T1 (hr) 2012-06-30
RS52265B (en) 2012-10-31
CN101166754A (zh) 2008-04-23
PT1799703E (pt) 2010-03-04
PT2361924E (pt) 2014-03-13
ZA200702591B (en) 2009-03-25
HK1156637A1 (en) 2012-06-15
PT2177528E (pt) 2012-03-19
ES2451006T3 (es) 2014-03-26
HK1140775A1 (en) 2010-10-22
NO20071632L (no) 2007-06-05
EP1799703B1 (en) 2010-01-06
DE602005018800D1 (de) 2010-02-25
JP5149008B2 (ja) 2013-02-20
BRPI0515033B1 (pt) 2021-05-25
PL1799703T3 (pl) 2010-06-30
PL2177528T3 (pl) 2012-09-28
JP2008512494A (ja) 2008-04-24
MX2007002760A (es) 2007-05-18
BRPI0515033A (pt) 2008-07-01
RS53248B (en) 2014-08-29
CY1110280T1 (el) 2015-01-14
IL181596A0 (en) 2007-07-04
US20060052586A1 (en) 2006-03-09
ATE454396T1 (de) 2010-01-15
HRP20100164T1 (hr) 2010-07-31
AU2005282249B2 (en) 2012-08-02
RU2007112956A (ru) 2008-10-20
ATE536363T1 (de) 2011-12-15
WO2006029393A3 (en) 2007-12-13
KR20070059137A (ko) 2007-06-11
CN101166754B (zh) 2014-04-23
CA2579656C (en) 2014-11-04
RU2388764C2 (ru) 2010-05-10
BRPI0515033A8 (pt) 2019-01-22
EP2361924B1 (en) 2013-12-11
EP1799703A4 (en) 2008-09-03
DK2177528T3 (da) 2012-03-26
US7495072B2 (en) 2009-02-24
SI2177528T1 (sl) 2012-04-30
WO2006029393A8 (en) 2007-04-19
EP1799703A2 (en) 2007-06-27
IL181596A (en) 2015-10-29
CA2579656A1 (en) 2006-03-16
WO2006029393A2 (en) 2006-03-16
IL241702A0 (en) 2015-11-30
SI1799703T1 (sl) 2010-04-30

Similar Documents

Publication Publication Date Title
HK1140775A1 (en) Process for the preparation of mixtures of trifluoroacetyl glatiramer acetate using purified hydrobromic acid
UA93669C2 (ru) Способ приготовления полипептидной смеси c использованием гидрогенолиза
MXPA04000597A (es) Peptidos novedosos de la proteina g del virus sincicial respiratorio (rsv), y su uso en una vacuna.
WO2003075944A3 (en) Interferon beta-like molecules for treatment of stroke
GB0001712D0 (en) Therapeutic peptides
WO2002066617A8 (en) Method for detecting a risk of hypertension and uses thereof
CY1115096T1 (el) Διαδικασια για την παρασκευη μιγματων trifluoroacetyl glatiramer acetate χρησιμοποιωντας καθαρισμενο υδροβρωμικο οξυ
ATE452903T1 (de) Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
EP1760087A4 (en) NEW PROTEIN COMPLEX AND USE OF THIS COMPLEX
WO2007026171A8 (en) Vdcc gamma-8 ion channel
WO2003037930A1 (fr) Nouveau polypeptide recepteur n-methyl-d-aspartate (nmda) du glutamate et gene codant pour celui-ci